AWS Brings ESM3 Language Models to Life Sciences

AWS has announced a collaboration with EvolutionaryScale to bring their cutting-edge language models to scientists and researchers in the field of biology. This partnership aims to advance applications in drug discovery, carbon capture, and more.

The collaboration introduces EvolutionaryScale’s ESM3, a state-of-the-art language model family, to AWS’s robust infrastructure. This includes enterprise-grade security, privacy measures, and purpose-built services for health and generative AI. 

The ESM3 model family, which includes generative, multimodal models, will be available on AWS platforms such as Amazon SageMaker and AWS HealthOmics, with support for Amazon Bedrock coming later this year.

ESM3 enables researchers to generate complex multi-domain proteins from scratch, create protein design workflows, and incorporate functional understanding. This innovative approach, termed "programmable biology," has the potential to significantly reduce the time and cost of bringing new therapeutics to market.

Customers can start using ESM3 through Amazon SageMaker and orchestrate automated drug discovery workflows via AWS HealthOmics. The collaboration also leverages AWS’s generative AI infrastructure, including high-performance GPU instances and ML accelerators like AWS Trainium and AWS Inferentia, ensuring efficient training and deployment of ESM3 models.

This initiative marks a significant leap in generative AI for biology, potentially accelerating drug discovery timelines and enabling novel therapeutic developments. The collaboration underscores AWS’s commitment to advancing generative AI across diverse industries, particularly in life sciences.

This is just the latest in AWS updates. Only a few days ago, AWS also launched a new AWS Generative AI Spotlight programme in the Asia Pacific and Japan (APJ) region, a four-week accelerator aimed at supporting early-stage startups in the region developing generative AI applications. In India, AWS is collaborating with venture capital firm Accel for this initiative.